Programming Living Drugs For Longevity: AI CAR-T Therapy

Programming Living Drugs For Longevity: Advancements In AI-Assisted CAR-T Therapy

September 6, 2025

Last month, a team of researchers at St. Jude Children’s Research Hospital solved a problem that had long stumped cellular medicine and impeded the efficacy of specific immunotherapies against cancer: most reprogrammed immune cells do not work as well as intended.

Traditional chimeric antigen receptor (CAR) T cell therapy utilizes T cells that target a tumor-specific protein antigen; however, targeting just one antigen is often insufficient to treat the tumor. In an effort to improve the outcomes of therapy, scientists have created CARs that target two proteins simultaneously, but these have encountered problems such as suboptimal cancer treatment. 

To address this, a team of investigators led by Giedre Krenciute, PhD, and M. Madan Babu, PhD, FRS, developed computational algorithms that screen many theoretical tandem CAR cell designs and rank top candidates based on their potential for optimization and other relevant factors prior to beginning costly and time-consuming laboratory testing. In a paper published in Molecular Therapy, the authors demonstrated that their computationally optimized CARs overcame prior challenges and functioned more effectively in treating animal models of cancer, proving that living drugs can now be programmed with artificial intelligence to target specific diseases with precision previously unattainable. Their algorithms screen approximately 1,000 therapeutic designs within days, identifying optimal cellular modifications before expensive laboratory testing begins.

This computational advance represents far more than improved cancer outcomes. While CAR-T therapy has already shown promise in autoimmune diseases where patients achieve complete remission, the ability to reliably engineer functional cellular therapies makes these applications more predictable and more effective. More significantly, this same approach is opening new research directions, including senolytic approaches that target cellular aging mechanisms directly.

Continue reading →

Revolutionizing Cancer Treatment: A Computational Leap in CAR-T Cell Therapy

September 2, 2025

In the ever-evolving landscape of cancer treatment, the emergence of Chimeric Antigen Receptor T-cell (CAR-T) therapy has marked a significant milestone. This immunotherapy harnesses the body’s own immune cells, reprogramming them to target and eliminate cancer cells.

While CAR-T therapies have shown remarkable success in treating certain blood cancers, their application to solid tumors has been met with challenges. A recent breakthrough by researchers at St. Jude Children’s Research Hospital offers a promising solution to enhance the efficacy of CAR-T therapies, particularly against hard-to-treat cancers.

Understanding the Challenge

Traditional CAR-T therapies typically target a single cancer-specific antigen present on the surface of tumor cells. However, many solid tumors exhibit heterogeneity, with varying expression of antigens across different cancer cells. This variability means that targeting a single antigen can leave subsets of tumor cells unaffected, leading to relapse and disease progression. To overcome this, scientists have explored the development of tandem bispecific CAR-T cells that can simultaneously target two distinct antigens, thereby broadening the scope of attack on the tumor.

The Computational Breakthrough

Designing effective tandem CAR-T cells has been a complex and resource-intensive process. The challenge lies in ensuring that the dual-targeting CAR constructs are expressed efficiently on the T-cell surface and retain their cancer-killing functionality. Addressing this, the team at St. Jude developed a novel computational tool that can rapidly design and optimize tandem CAR constructs. This tool systematically screens numerous theoretical designs, evaluating their potential efficacy and selecting the most promising candidates for further development.

Dr. Giedre Krenciute, a co-corresponding author of the study, emphasized the significance of this advancement, stating, “We have developed and validated a computational tool that can significantly accelerate the design of tandem CAR constructs with improved surface expression and anti-tumor function.” The research, published in Molecular Therapy, demonstrates how computational optimization can streamline the development of CAR-T therapies, making them more effective and accessible.

Experimental Validation

To validate the computational predictions, the researchers synthesized the top-ranked tandem CAR constructs and tested them in preclinical models. The results were promising; the optimized CAR-T cells exhibited enhanced surface expression and superior anti-tumor activity compared to traditional single-target CAR-T cells. These findings underscore the potential of computational tools in accelerating the development of more potent and versatile CAR-T therapies.

Implications for Cancer Treatment

The ability to design CAR-T cells that can target multiple antigens simultaneously opens new avenues for treating a broader range of cancers, including those that have been resistant to conventional therapies. By improving the specificity and efficacy of CAR-T cells, this approach could lead to better patient outcomes, reduced relapse rates, and potentially, cures for cancers that currently have limited treatment options.

Furthermore, the integration of computational tools into the design process exemplifies the growing role of artificial intelligence and machine learning in biomedical research. These technologies enable researchers to analyze vast datasets, predict molecular interactions, and optimize therapeutic strategies with unprecedented speed and accuracy.

Looking Ahead

While the computational tool developed by St. Jude represents a significant step forward, ongoing research is essential to refine and expand its applications. Future studies will focus on testing the optimized tandem CAR-T cells in clinical trials to assess their safety and efficacy in humans. Additionally, researchers aim to explore the potential of combining this approach with other therapeutic modalities, such as checkpoint inhibitors or targeted therapies, to create more comprehensive treatment regimens.

In conclusion, the development of a computational tool to enhance CAR-T cell therapy marks a pivotal moment in cancer treatment. By leveraging the power of computational design, researchers are paving the way for more effective and personalized therapies that could transform the prognosis for patients with hard-to-treat cancers. As this field continues to evolve, the integration of computational tools will likely become standard practice, ushering in a new era of precision medicine in oncology.

Sources:

Cannabis and Age-Related Disease: Clinical Insights Into an Emerging Therapeutic Frontier

August 22, 2025

As the landscape of longevity medicine continues to evolve, there are very few topics as contested as the role of cannabis-based medicinal products in age-related disease management. While the use of cannabis in younger populations has historically raised concerns about neurocognitive effects, recent evidence suggests that older adults may benefit from its unique pharmacologic profile.

For clinicians working at the intersection of aging, chronic disease, and patient quality of life, the potential applications of cannabis-based medicinal products warrant careful exploration.

The Endocannabinoid System and Aging

Central to cannabis’ therapeutic potential is the endocannabinoid system (ECS). The ECS is a network of receptors, ligands, and enzymes that regulate homeostasis across multiple physiologic systems. Aging is associated with dysregulation of the ECS, including reduced CB1 receptor expression and altered signaling pathways. These changes may contribute to increased vulnerability to inflammation, sleep disturbance, chronic pain, and neuropsychiatric symptoms in older adults.

Cannabinoid compounds such as THC and CBD act on these pathways in distinct ways. Evidence suggests that cannabis may restore some of the regulatory balance lost with age in older adults. This is in contrast to younger populations, where ECS disruption from heavy cannabis use can impair cognitive development and long-term brain health.

For longevity-focused practitioners, this age-dependent response highlights the importance of timing, context, and dosing in therapeutic application.

Clinical Applications in Age-Related Disease

Research on cannabis and aging is still in its early stages, but several domains of potential benefit are emerging:

  • Sleep Disorders: Insomnia prevalence rises with age and correlates with poor cardiometabolic outcomes and accelerated cognitive decline. Small-scale trials suggest that cannabinoids may improve sleep latency and quality, potentially serving as adjunctive therapy when traditional pharmacologics are poorly tolerated.
  • Neuropsychiatric Symptoms: Anxiety and depression frequently complicate aging trajectories and chronic illness. Preliminary evidence indicates that CBD, in particular, may mitigate these symptoms without the sedative risks associated with benzodiazepines.
  • Chronic Pain and Inflammation: Musculoskeletal degeneration, neuropathy, and inflammatory arthritis represent leading drivers of diminished healthspan. CBMPs may reduce pain perception and modulate inflammatory pathways, offering a non-opioid alternative for select patients.

Importantly, these therapeutic opportunities must be weighed against the risk of cognitive impairment, falls, and polypharmacy interactions, particularly in frail or multimorbid patients.

Challenges in Evidence and Clinical Adoption

Despite promising signals, the evidence base remains limited. Most studies are small, heterogeneous, and constrained by inconsistent terminology. Terms such as “recreational use,” “heavy use,” or “older adults” lack clinical precision, making it difficult to translate findings into actionable protocols. Standardized dosing frameworks, age-stratified cohorts, and randomized controlled trials are needed to clarify efficacy and safety.

The lack of trial data presents both a barrier and an opportunity for clinicians. Those who integrate cannabis into practice must do so with an emphasis on personalized risk-benefit assessment and meticulous patient monitoring.

Practical Considerations for Longevity Medicine

Physicians interested in integrating cannabis-based medicinal products into longevity practice should approach cautiously but proactively:

  • Patient Selection: Older adults with refractory pain, insomnia, or anxiety who have not responded to standard therapies may represent appropriate candidates for careful cannabis trials.
  • Formulation and Delivery: Non-inhaled forms (e.g., capsules, oils, or microdosed preparations) may reduce respiratory risk and improve dose consistency.
  • Monitoring: Close tracking of cognition, balance, cardiovascular status, and drug-drug interactions is critical, particularly when patients are on polypharmacy regimens.

By embedding cannabis discussions within a broader framework of patient-centered, longevity-focused care, clinicians can navigate this evolving field responsibly.

Looking Ahead

Cannabis is not a panacea for aging. Yet, in the right patients it may offer meaningful improvements in healthspan by addressing sleep, mood, pain, and inflammation which are core domains of longevity medicine. As research deepens, physicians will need to discern where cannabis fits among other emerging therapies and how to integrate its use into evidence-based protocols.

The future of longevity care depends on leveraging every validated tool at our disposal. Cannabis, once dismissed as fringe, may soon take its place as a legitimate adjunct in the fight against age-related decline.

Sources: